Amrubicin is a synthetic anthracycline which has been shown in preclinical studies to have broad-spectrum anti-tumor activity and a lower potential for cardiotoxicity as compared to doxorubicin. Amrubicin Shows Promise in Relapsed or Refractory Small Cell Lung Cancer.Amrubicin acts by inhibiting topoisomerase II, and has been compared in clinical trials with topotecan, a Topoisomerase I inhibitor.It has also been studied for the treatment of bladder carcinoma and gastric cancer. Amrubicin appears to have significant activity against invasive thymoma.
| Molecular Weight | 483.47 |
| Formula | C25H25NO9 |
| CAS Number | 110267-81-7 |
| Form | Solid |
| Solubility (25°C) | DMSO |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
| Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
| Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
| Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
| Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
| Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
| Related Topoisomerase Products |
|---|
| ICRF-193
ICRF-193 is an TopoII inhibitor. |
| Topoisomerase II inhibitor 15
Topoisomerase II inhibitor 15 is a Topoisomerase II inhibitor. |
| Topoisomerase II inhibitor 13
Topoisomerase II inhibitor 13 is a topoisomerase II (Topo II) inhibitor. |
| ICRF-196
ICRF-196 is an racemic mixture of the (S,S)- and (R,R)-isomers of ICRF-193. |
| Cholesteryl hemisuccinate
Cholesteryl hemisuccinate is a with hepatoprotective an anticancer activity. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
